Ultragenyx Pharmaceutical Inc. is the subject of a securities class action lawsuit stemming from the company's December 26, 2025 announcement of failed Phase 3 clinical trials for setrusumab (UX143), its investigational treatment for osteogenesis imperfecta. The disclosure, which the lawsuit alleges involved material information that should have been previously disclosed, triggered a significant market reaction, with the stock declining 42% from $34.19 to $19.72 per share in the trading session following the announcement.
The litigation centers on claims that Ultragenyx failed to adequately inform investors about issues with the setrusumab program prior to the public disclosure. Investors who sustained losses exceeding $100,000 during the relevant period have until April 6, 2026 to submit applications to serve as lead plaintiff in the case. Lead plaintiff status is typically pursued by investors with substantial financial stakes in the outcome of the litigation.
The case highlights the regulatory and disclosure requirements facing pharmaceutical companies conducting clinical trials. Companies are generally required to disclose material developments in drug development programs that could reasonably impact investor decision-making. The outcome of this litigation may have implications for how biopharmaceutical firms communicate trial progress to shareholders.